Applied Genetic Technologies Corp(NASDAQ:AGTC) announced the earnings results for Fiscal Year 2016 and Q4. The results came in during After-hours on Sep 12, 2016. Company reported revenue of $12.11M. Analysts estimated a revenue of $12.93M. Earnings per share were $0.15. Analysts had estimated an EPS of $0.07.
Applied Genetic Technologies Corp (AGTC) made into the market gainers list on Tuesdays trading session with the shares advancing 2.80% or 0.24 points. Due to strong positive momentum, the stock ended at $8.82, which is also near the day’s high of $9.02. The stock began the session at $8.69 and the volume stood at 3,49,022 shares. The 52-week high of the shares is $21.43 and the 52 week low is $8.5. The company has a current market capitalization of $159 M and it has 1,80,53,284 shares in outstanding.
Several Insider Transactions has been reported to the SEC. On Feb 12, 2015, Plc Glaxosmithkline (10% owner) sold 50,000 shares at $21.14 per share price.Also, On Jan 26, 2015, Daniel L Menichella (V.P. & Chief Business Officer) sold 1,996 shares at $24.90 per share price.
Applied Genetic Technologies Corp is a United States-based clinical stage biotechnology company. The Company develops gene therapy products for the treatment of inherited and acquired diseases. Its products are used to treat Alpha One Antitrypsin Deficiency (Alpha-1) a respiratory disease caused by deficiencies in the tissue protective protein alpha one antitrypsin; and Lebers congenital amaurosis an inherited condition causing early blindness. Its products also used to treat X-linked retinoschisis an inherited form of retinal degeneration affecting young males with poor vision either in infancy or at school age; and achromatopsia an inherited condition that is associated with color blindness visual acuity loss and extreme light sensitivity resulting in daytime blindness.